CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV

Feb 18, 2014 8:05am EST

CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors

Feb 13, 2014 8:05am EST

CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM Eastern

Feb 05, 2014 7:35am EST

CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140

Jan 28, 2014 8:05am EST

CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific

Jan 08, 2014 8:05am EST

CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA

Oct 30, 2013 3:59pm EDT

CytoDyn Inc. Appoints David Feigal, M.D., as Chief Medical Officer

Oct 25, 2013 9:00am EDT

CytoDyn Inc. Completes $14.5 Million Private Equity Offering

Oct 24, 2013 7:40pm EDT

CytoDyn Inc. Appoints Bruce Montgomery, M.D. to its Board of Directors

Oct 03, 2013 3:15pm EDT

CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors

Jun 17, 2013 4:52pm EDT